Dr. Thomas Insel, who directed the National Institute of Psychological Wellbeing from 2002 to 2015 and is an advisor to and investor in Compass Pathways, a biotechnology firm running clinical trials of psilocybin, the psychoactive component of magic mushrooms, thinks these concerns say more about Lykos when compared to the copyright field in genera